Li-Fraumeni syndrome is classically defined by germline <i>TP53</i> mutations and early-onset malignancies, yet the clinical spectrum has expanded to include atypical and late-onset presentations that challenge standard diagnostic criteria. This evidence concerns the gene TP53 and Li-Fraumeni syndrome.